REPLIGEN CORP Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
REPLIGEN CORP (RGEN) had Operating Leases, Future Minimum Payments, Remainder of Fiscal Year of $893.00 thousand as of 2018-09-30, per its 10-Q filed 2018-11-01.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2018-11-01
- 2018-09-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $893.00K.
- 2018-06-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $1.82M.
- 2018-03-31: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $3.19M.
- 2017-09-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $939.00K.
| Period end | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year |
|---|---|
| 2018-09-30 | $893.00K 10-Q · filed 2018-11-01 |
| 2018-06-30 | $1.82M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $3.19M 10-Q · filed 2018-05-08 |
| 2017-09-30 | $939.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $1.35M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $2.03M 10-Q · filed 2017-05-04 |
| 2016-09-30 | $622.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $2.03M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $2.13M 10-Q · filed 2016-05-05 |
| 2015-09-30 | $586.00K 10-Q · filed 2015-11-05 |
| 2015-06-30 | $1.18M 10-Q · filed 2015-08-06 |
| 2014-09-30 | $343.00K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $655.00K 10-Q · filed 2014-08-11 |
| 2014-03-31 | $908.00K 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |